Miglustat Dipharma Unión Europea - danés - EMA (European Medicines Agency)

miglustat dipharma

dipharma arzneimittel gmbh - miglustat - gaucher sygdom - andre fordøjelseskanaler og stofskifteprodukter - miglustat dipharma er angivet for den mundtlige behandling af voksne patienter med mild til moderat type 1 gaucher sygdom. miglustat dipharma kan kun anvendes i behandling af patienter, for hvem enzymsubstitutionsbehandlingen er uegnet. miglustat dipharma er indiceret til behandling af progressive neurologiske forstyrrelser hos voksne patienter, og pædiatriske patienter med niemann-picks sygdom type c.

Erlotinib "Medical Valley" 25 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

erlotinib "medical valley" 25 mg filmovertrukne tabletter

medical valley invest ab - erlotinibhydrochlorid - filmovertrukne tabletter - 25 mg

Lopid 600 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

lopid 600 mg filmovertrukne tabletter

nordic prime aps - gemfibrozil - filmovertrukne tabletter - 600 mg

Lopid 300 mg kapsler, h?rde Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

lopid 300 mg kapsler, h?rde

orifarm a/s - gemfibrozil - kapsler, hårde - 300 mg

Metadon "2care4" 20 mg tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

metadon "2care4" 20 mg tabletter

2care4 generics aps - methadonhydrochlorid - tabletter - 20 mg

Metadon "2care4" 5 mg tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

metadon "2care4" 5 mg tabletter

2care4 generics aps - methadonhydrochlorid - tabletter - 5 mg

Piqray Unión Europea - danés - EMA (European Medicines Agency)

piqray

novartis europharm limited  - alpelisib - bryst neoplasmer - antineoplastiske midler - piqray er indiceret i kombination med fulvestrant til behandling af postmenopausale kvinder, og mænd, med hormon receptor (hr)-positiv, human epidermal growth factor receptor 2 (her2)-negative, lokalt fremskreden eller metastatisk brystkræft med en pik3ca mutation efter sygdommens progression følgende endokrine behandling som monoterapi (se afsnit 5.

Trodelvy Unión Europea - danés - EMA (European Medicines Agency)

trodelvy

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastiske midler - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Zokinvy Unión Europea - danés - EMA (European Medicines Agency)

zokinvy

eigerbio europe limited - lonafarnib - progeria; laminopathies - andre alimentary tract and metabolism produkter, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Desmopressin "Teva" 0,1 mg tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

desmopressin "teva" 0,1 mg tabletter

orifarm a/s - desmopressinacetattrihydrat - tabletter - 0,1 mg